Drugs / LANOPEPDEN
LANOPEPDEN
also known as
GSK1322322 · Gsk-1322322 mesylate · GSK-1322322B · GSK-1322322J · Gsk-322 · GSK1322322 (freebase) · GSK1322322 (mesylate salt) · Lanopepden mesilate · +2 more
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT01953809 | Aug 2014 → Mar 2015 | bacterial infectious disease | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 1 | NCT01803399 | Aug → Dec 2014 | bacterial infectious disease | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 1 | NCT01818011 | Aug → Oct 2013 | bacterial infectious disease | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT01663389 | Aug → Oct 2012 | bacterial infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01648179 | Mar → May 2012 | bacterial infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01610388 | Sep 2011 → Jan 2012 | bacterial infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00896558 | May → Sep 2009 | bacterial infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00924911 | Apr → Jul 2009 | bacterial infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01209078 | Aug 2010 → Jan 2011 | skin disease caused by bacterial infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LANOPEPDEN | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301608 ↗ |
| Known as | Gsk-1322322 mesylate | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301608 ↗ |
| Known as | GSK-1322322B | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301608 ↗ |
| Known as | GSK-1322322J | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301608 ↗ |
| Known as | Gsk-322 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301608 ↗ |
| Known as | GSK1322322 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00924911 ↗ |
| Known as | GSK1322322 (freebase) | “GSK1322322 (freebase) tablets” NCT01648179 ↗ |
| Known as | GSK1322322 (mesylate salt) | “GSK1322322 (mesylate salt) Powder for Injection” NCT01648179 ↗ |
| Known as | Lanopepden mesilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301608 ↗ |
| Known as | LANOPEPDEN MESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301608 ↗ |
| Known as | Lanopepdene | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301608 ↗ |
| Action | Inhibit | “GSK1322322 is a potent peptide deformylase inhibitor” PMID 24189245 ↗ Nov 2013 |
| Modality | Small molecule | — CHEMBL3301608 ↗ |
| Route | Oral | “1000mg oral GSK1322322/placebo” NCT01610388 ↗ |